Investors Chronicle12 Mar 2026 19:16
Simon Thompson has written about what he considers to be LST's potential in the past. He has written again yesterday following the raise. He notes the dilution but remains of the view that the business has strong potential. He notes that Shore Capital believes operating profit could increase as follows - £0.44mn (2026), £1.28mn (2027) and £2.95mn (2029) based on revenue of £11.7mn (2026), £15.6mn (2027) and £21.5mn (2028), with a fair value of 4.6p a share. ST says he thinks that is a conservative estimate, and he suggests averaging down via the retail offer.
I'm not going to do that as my position in the company is too large to justify more investment. After the shock of yesterday, it is good to see some positivity in this article, but I think what he says needs to be caveated:
1. Brokers' forecasts often seem to me to be somewhat divorced from market expectations, and Shore's 4.6p following the raise seems somewhat outlandish given that it was a long way below that before the raise;
2. The projected figures for operating profit and revenue must be based on the assumption of excellent execution in securing contracts in the quoted pipeline and delivering on those contracts. We don't I think have much evidence to suggest that LST can deliver on that - it might be able to or might not, but there isn't much visible history to go on;
3. My hope is that the significant fall in revenue in H2 2025 has a specific reason - the delays in BSR regulatory approvals. which LST has mentioned in the past, and that these delays will be resolved. However, it isn't really clear why BSR approval is an issue for LST particularly, as approval is required for each building project involving a higher risk building. Is approval being delayed in projects LST is involved in because of the use of Injectaclad, and the BSR is ensuring that Injectaclad is an appropriate solution and once it gets comfortable with it, approvals for future projects will be agreed more quickly or because there is just a lot of higher risk building projects being considered and the BSR doesn't have capacity to give approvals quickly enough. There's quite a lot of uncertainty around this. May be it will cleared up when the final accounts are presented - certainly there should be some explanation given for the very big drop in H2 revenue;
4. the final point to make is that even if the revenue and profit figures are achieved, this is a micro-cap and likely to remain so for a very long while if not permanently. As such it is always going to suffer a share price discount. In LST's case, the very abrupt and significant discounting and dilution of the existing shareholders will also probably have a drag effect on the share price for a long time, even if the business prospers.
Hopefully it will recover